Pseudomonas aeruginosa enfeksiyonlarında optimize edilmiş piperasilin-tazobaktam dozlamasının klinik sonuçları: Öncesi-sonrası kohort çalışması


Creative Commons License

Arı P., Eskiömeroğlu Ş., Ergen B., Tuncel T., Ertürk Şengel B., Yağçı Çağlayık D., ...Daha Fazla

ESCP, Lisbon, Portekiz, 12 - 14 Ekim 2026, ss.1, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Lisbon
  • Basıldığı Ülke: Portekiz
  • Sayfa Sayıları: ss.1
  • Marmara Üniversitesi Adresli: Evet

Özet

BACKGROUND:

Pseudomonas aeruginosa is one of the leading pathogens for deaths attributed to resistance (Murray et al., 2022). Extended or continuous of beta lactam antibiotics has been associated with improved target concentration attainment and lower mortality in patients with sepsis and severe infections (Hyun et al., 2023).

AIM:

This study aimed to evaluate the clinical benefits of a loading dose followed by extended infusion of piperasilin tazobactam in patients with P.aeruginosa isolated from blood or sputum cultures, highlighting the collaborative role of infectious disease specialists and clinical pharmacists in optimizing antimicrobial therapy.

METHOD:

This study consisted of two consecutived 3 month periods. In the retrospective (control) period, patients with P. aeruginosa growth received piperacillin-tazobactam via traditional infusion. In the subsequent prospective period, an optimized dosing protocol designed through multidisciplinary collaboration was implemented, where patients received a loading dose followed by an extended infusion. Patients requiring escalation/de-escalation therapy or those with P. aeruginosa isolated from cultures other than blood or sputum were excluded.

RESULTS:

Each study period lasted 3 months. A total of 47 patients were assessed for eligibility, including 25 patients in the retrospective cohort and 22 in the prospective cohort. Following exclusions due to additional microbial growth (n=4) and adverse events (n=3), 40 patients were included in the final analysis (20 per group). The median age of the study population was 66 years, and 60.4% were male. There were no significant differences between the groups in Charlson Comorbidity Index scores (median 4 vs 5, p = 0.4; Mann–Whitney U test). Clinical non-response occurred in 2 of 20 patients (10%) in the prospective group and 9 of 20 patients (45%) in the retrospective group, representing a statistically significant reduction in the prospective cohort (Fisher’s exact test, p = 0.03). Linear regression analysis demonstrated that the cost model was statistically significant, F(2, 37) = 28.68, p < 0.001, and explained 60.79% of the variance in cost (R² = 0.608)

CONCLUSION:

Implementing a loading dose followed by an extended infusion protocol significantly improves clinical response rates in severe P. aeruginosa infections. These findings underscore the critical value of joint interventions between infectious disease physicians and clinical pharmacists in translating pharmacokinetics/ pharmacodynamics principles into bedside practice, ultimately optimizing treatment outcomes against high-risk resistant pathogens.